Combined mannitol and deferoxamine therapy for myohemoglobinuric renal injury and oxidant tubular stress. Mechanistic and therapeutic implications.
Mannitol (M) and deferoxamine (DFO) can each protect against myohemoglobinuric acute renal failure (MH-ARF). This study assessed M-DFO interactions during MH-ARF to help discern mechanisms of renal injury, and to define whether M + DFO exerts additive or synergistic antioxidant/cytoprotective effect...
Enregistré dans:
| Publié dans: | J Clin Invest |
|---|---|
| Auteur principal: | |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
American Society for Clinical Investigation
1992
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC329921/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/1325995/ https://ncbi.nlm.nih.govhttps://doi.org/10.1172/JCI115942 |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|
